Drug Profile
RT 100
Alternative Names: Ad5-AC6; Ad5.hAC6; Adenylate cyclase gene therapy - Renova; RT100Latest Information Update: 05 Oct 2020
Price :
$50
*
At a glance
- Originator Renova Therapeutics
- Class Gene therapies
- Mechanism of Action Adenylate cyclase expression stimulants; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Heart failure
Most Recent Events
- 05 Oct 2020 Phase II development for Heart failure is still ongoing in USA (Renova Therapeutics pipeline, September 2020)
- 05 Jun 2019 Renova Therapeutics withdraws the phase III FLOURISH trial for Heart failure in USA due to the clinical development plans and strategy for RT 100 being re-evaluated (Intracoronary) (NCT03360448)
- 19 Dec 2017 RT 100 receives Fast Track designation for Heart failure [Intracoronary] in USA